AXSOME THERAPEUTICS, INC. Proceeds from Long-term Lines of Credit
AXSOME THERAPEUTICS, INC. (AXSM) reported Proceeds from Long-term Lines of Credit of $140.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLongTermLinesOfCredit · last filed 2026-08-10
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2026-06-30 was $70.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2026-03-31 was $70.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2025-12-31 was $70.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for the quarter ending 2025-09-30 was $70.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2025 was $330.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2023 was $85.00M, a 88.89% increase from fiscal 2022.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2022 was $45.00M.
- AXSOME THERAPEUTICS, INC. proceeds from long-term lines of credit for fiscal 2020 was $50.00M.
| Period end | Proceeds from Long-term Lines of Credit 3 month | Proceeds from Long-term Lines of Credit 6 month | Proceeds from Long-term Lines of Credit 9 month | Proceeds from Long-term Lines of Credit 12 month |
|---|---|---|---|---|
| 2026-06-30 | $70.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $140.00M 10-Q · filed 2026-08-10 | $210.00M derived: sum of 3 quarters · filed 2026-08-10 | $280.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $70.00M 10-Q · filed 2026-05-04 | $140.00M derived: sum of 2 quarters · filed 2026-05-04 | $210.00M derived: sum of 3 quarters · filed 2026-05-04 | |
| 2025-12-31 | $70.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $140.00M derived: sum of 2 quarters · filed 2026-02-23 | $330.00M 10-K · filed 2026-02-23 | |
| 2025-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $260.00M 10-Q · filed 2025-11-03 | ||
| 2025-06-30 | $190.00M 10-Q · filed 2026-08-10 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $30.00M derived: sum of 3 quarters · filed 2026-02-23 | $85.00M 10-K · filed 2026-02-23 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $30.00M derived: sum of 2 quarters · filed 2024-11-12 | $85.00M 10-Q · filed 2024-11-12 | $85.00M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $85.00M 10-Q · filed 2024-08-05 | $85.00M derived: sum of 3 quarters · filed 2025-02-18 | $85.00M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $55.00M 10-Q · filed 2024-05-06 | $55.00M derived: sum of 2 quarters · filed 2025-02-18 | $55.00M derived: sum of 3 quarters · filed 2025-02-18 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $0.00 derived: sum of 2 quarters · filed 2025-02-18 | $45.00M 10-K · filed 2025-02-18 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $45.00M 10-Q · filed 2023-11-06 | ||
| 2022-06-30 | $45.00M 10-Q · filed 2023-08-07 | |||
| 2020-12-31 | $50.00M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |